Mounjaro long-term effects and cancer risk: what the research shows

Step 1: where the cancer concern originally came from

The worry usually traces back to a rodent study conducted during Mounjaro's development. In high-dose, long-duration animal experiments, GLP-1 receptor agonists (including tirzepatide) were associated with the development of C-cell thyroid tumours (medullary thyroid carcinoma, or MTC) in rats and mice. That finding is documented in the Mounjaro SmPC on the eMC, and it is why anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, is excluded from treatment.

A misconception worth gently setting aside: many people read those rodent findings and conclude that tirzepatide causes thyroid cancer in humans. Rodent C-cells respond to GLP-1 stimulation in a way that human C-cells do not, because human thyroid cells have a far lower density of GLP-1 receptors. Regulators on both sides of the Atlantic examined the mechanism and concluded the animal data do not directly translate. Human clinical trials and post-marketing surveillance have not produced a corresponding signal. That does not make the question irrelevant, it makes it answerable, and the answer so far is reassuring.

If you want to read more about Mounjaro's broader profile, our page covering what Mounjaro does in the body sets this in fuller context.

Step 2: what the large human trials and registries actually found

The SURMOUNT clinical programme, which enrolled thousands of adults across multiple trials including SURMOUNT-1 (2,539 participants, 72 weeks), did not identify an elevated cancer incidence in tirzepatide-treated participants compared with placebo. The published SURMOUNT-1 results in the New England Journal of Medicine reported no concerning pattern of malignancy. These were the trials that supported UK licensing; NICE reviewed them in full for its technology appraisal TA1026, published in December 2024.

Post-authorisation safety studies are now accumulating, and the picture they paint is one the obesity medicine community has found notable: a growing body of epidemiological data (primarily from semaglutide and other GLP-1 receptor agonists, which have a longer post-market history than tirzepatide) suggests possible associations with reduced incidence of certain obesity-related cancers, including colorectal cancer. These findings are preliminary, observational, and not yet sufficient to draw firm conclusions for tirzepatide specifically. They are not a reason to start treatment, but they are a reason to watch this space rather than assume the worst.

Our fuller discussion of Mounjaro's long-term profile covers what the current follow-up periods do and do not tell us.

Step 3: how to think about long-term data gaps sensibly

Mounjaro received its UK licence in November 2023. That means the longest real-world human exposure data stretch to roughly two to three years for the earliest participants. For a medicine intended for long-term use, that is a relatively short window. No responsible clinician or regulator would claim certainty about effects that take a decade or more to manifest, and none do.

What regulators do is build monitoring into the licence. The Black Triangle status attached to Mounjaro means the MHRA collects and reviews safety data more intensively than for established medicines. Prescribers are required to report adverse events; patients can report directly via Yellow Card. This is how signals, if they exist, get caught early. It is a different kind of reassurance from a 20-year dataset, but it is active reassurance rather than silence.

Those weighing up the cost and clinical picture of long-term treatment may find our Mounjaro cost comparison useful reading alongside this page. Treatment decisions involve more than one variable.

Step 4: where obesity itself fits into the cancer conversation

This is the part the cancer-and-tirzepatide question often misses. Obesity is itself a recognised risk factor for at least 13 types of cancer, including cancers of the bowel, kidney, liver, oesophagus, and womb lining. The biological pathways are reasonably well understood: chronic low-grade inflammation, elevated insulin and IGF-1 signalling, and hormonal dysregulation all play a role. A medicine that produces sustained, clinically meaningful weight reduction (in the SURMOUNT-1 trial, average reductions were around 20% of body weight at the highest dose) could, in principle, reduce exposure to some of those pathways over time.

That is not a claim about cancer prevention. It is context. The point is that framing tirzepatide as a cancer risk while ignoring the cancer risks associated with untreated obesity gives a distorted picture. A clinician's job is to weigh both sides. For anyone thinking about what this medicine might mean over years rather than weeks, our page on what the long-term effects of Mounjaro look like is a reasonable starting point, and you can read a dedicated overview of the long-term effects of Mounjaro, covering what sustained use means for your health over time, before exploring tirzepatide's mechanism and evidence base in more depth there too.

As with all prescription medicines, the right place to discuss your individual risk profile is with a prescriber who has your full medical history in front of them. If you'd like to speak with ours, check your eligibility for a free consultation and a GPhC-registered Independent Prescriber will review your details the same day.